Cesc_febrer

Bryan Johnson stopped his GLP-1 experiment after 3 weeks. Sleep score down. Heart rate up a few beats. HRV dropped slightly. With respect Bryan, 3 weeks is nothing. Not almost nothing. Literally nothing. This is one of the most studied classes of compounds in modern medicine. The cardiovascular outcome data spans years and involves hundreds of thousands of patients. The results are overwhelmingly positive. Reduced cardiac events. Lower inflammation. Improved metabolic markers across the board. And we are drawing conclusions from 3 weeks of biometric fluctuation. Your digestion changed. Your appetite changed. Your caloric intake shifted even if your food choices did not. Your body was in full adaptation mode for the entire duration of this experiment. HRV and resting heart rate are downstream of every single one of those variables simultaneously. You did not test the compound. You tested what it feels like to adapt to the compound. Those are completely different experiments. The adaptation window for GLP-1 agonists is documented at 8 to 12 weeks minimum. Whether specific HRV and cardiac metrics fully normalize beyond that window is still an open and genuinely interesting scientific question. But what is not an open question is this; the long term cardiovascular outcome data on this class of compounds is among the most positive in modern pharmacology. And here is what the conversation keeps missing entirely. For lean healthy people the single strongest argument for tirzepatide has nothing to do with weight loss. It is direct cardiovascular protection independent of body composition changes. The trial data shows meaningful reduction in heart attack and stroke risk through mechanisms that operate regardless of how much weight is lost. You are taking out an insurance policy on your cardiovascular system at the cellular and vascular level. The second reason is equally compelling. Every longevity protocol in existence points to the same conclusion. Maintaining a lean body composition without chronic caloric excess is one of the most powerful determinants of long term health and lifespan. We know this. The science is settled. But doing it through constant willpower, mental bandwidth, and friction is itself a source of chronic stress. That stress impairs quality of life. It taxes the nervous system. It makes adherence a burden rather than a default. Tirzepatide does not just help you stay lean. It makes the entire longevity eating protocol seamless. Effortless. Enjoyable. Your appetite finally aligns with your goals instead of fighting them every single day. Removing that friction is not a shortcut. It is an upgrade to every dimension of the protocol simultaneously. 3 weeks of adaptation noise is not the experiment. The experiment is what this compound does to your cardiovascular system, your metabolic health, and your quality of life over years. If you are going to do the work Bryan, do the work.

Por qué será que una mujer de 35 años presenta un ictus isquémico en territorio de la ACM-D? No fuma, no tiene arritmias ni shunt DI ni HTA/DLP/DM. AP: solo SOPQ (nunca ha tomado ACOs). En RM hecha por el ictus se ve tumor en ángulo/cavum de Mekel y nódulo 10 mm en hipófisis.

Esto es lo máximo a lo que puede aspirar $AMZN en el sector de la salud, meramente a distribuir medicamentos comerciales. $NVO también es a lo único que puede aspirar. A buscar el máximo número de distribuidores. El sector no se dirige a esto, está transformándose en medicina personalizada.

Por cada € cotizado, el actual pensionista recibe 1.62 €. Fin de la cita.